



# **SmartPA Criteria Proposal**

Drug/Drug Class:	ACE Inhibitors and ACE Inhibitors/ Diuretic Combinations PDL Edit	
First Implementation Date:	March 12, 2003	
Proposed Date:	September 16, 2021	
Prepared For:	MO HealthNet	
Prepared By:	MO HealthNet/Conduent	
Criteria Status:	<ul> <li>□Existing Criteria</li> <li>☑Revision of Existing Criteria</li> <li>□New Criteria</li> </ul>	

# **Executive Summary**

- Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.
- Why Issue Angiotensin-converting-enzyme-inhibitors (ACEIs) block the activation of the renin-aldosterone system, which is a mediator of blood pressure. In addition to their effects on blood pressure, ACEIs are also thought to have beneficial ventricular effects following myocardial infarction (MI), in patients with heart failure, and in preventing the progression of diabetic nephropathy. Professional associations, such as the American Heart Association, and the American Diabetes Association, as well as cardiology specialists, recommend ACEIs as the standard of care for patients with recent MI, in patients at high risk for cardiovascular events, and in patients with diabetic nephropathy. ACEIs have been shown to be efficacious when used alone or in combination with diuretics. These fixed-dose combinations of diuretics and ACEIs are approved for the management of hypertension but are not indicated as initial therapy.

Total program savings for the PDL classes will be regularly reviewed.

Program-	Preferred Agents	Non-Preferred Agents
Specific	Benazepril	Accupril <sup>®</sup>
Information:	Benazepril/HCTZ	Accuretic <sup>®</sup>
	Enalapril Tabs	Altace <sup>®</sup>
	Enalapril/HCTZ	Captopril
	Fosinopril	Captopril/HCTZ
	Lisinopril	• Epaned <sup>®</sup>
	Lisinopril/HCTZ	Enalapril Soln
	Quinapril	Fosinopril/HCTZ
	Ramipril	Lotensin <sup>®</sup>
		Lotensin HCT <sup>®</sup>
		Moexipril
		Moexipril/HCTZ
		Perindopril
		<ul> <li>Trandolapril</li> <li>Zestril<sup>®</sup></li> </ul>
Type of Criteria:	Increased risk of ADE	Preferred Drug List
	Appropriate Indications	Clinical Edit
Data Sources:	Only Administrative Databases	Databases + Prescriber-Supplied

## Setting & Popu

- Drug class for review: ACE Inhibitors and ACE Inhibitors/ Diuretic Combinations
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 4 or more preferred agents:
  - Documented trial period for preferred agents OR
  - Documented ADE/ADR to preferred agents AND
- For Qbrelis or Epaned: Clinical Consultant Review for participants aged 10 years or older

## Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met
- Claim exceeds maximum dosing limitation for the following:

Drug Description	Generic Equivalent	Max Dosing Limitation		
ZESTORETIC 10 MG/12.5 MG	LISINOPRIL/HCTZ	1 tablet per day		
ZESTORETIC 20 MG/12.5 MG	LISINOPRIL/HCTZ	4 tablets per day		
ZESTORETIC 20 MG/25 MG	LISINOPRIL/HCTZ	2 tablets per day		
UNIVASC 7.5 MG	MOEXIPRIL	1 tablet per day		
UNIVASC 15 MG	MOEXIPRIL	2 tablets per day		

#### SmartPA PDL Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent<sup>TM</sup> and Conduent Design<sup>TM</sup> are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

## **Required Documentation**

Laboratory Results: MedWatch Form:

\_\_\_\_

Progress Notes: Other:

# **Disposition of Edit**

Denial: Exception Code "0160" (Preferred Drug List) Rule Type: PDL

# **Default Approval Period**

1 year

## References

- 1. Evidence-Based Medicine and Fiscal Analysis: "Angiotensin Converting Enzyme Inhibitor Agents Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; July 2021.
- Evidence-Based Medicine and Fiscal Analysis: "Angiotensin Converting Enzyme Inhibitor/Diuretic Combination Agents – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; July 2021.
- 3. Evidence-Based Medicine Analysis: "ACE Inhibitors", UMKC-DIC; June 2020.
- 4. Evidence-Based Medicine Analysis: "Angiotensin Converting Enzyme Inhibitors (ACEI) and Diuretic Combinations", UMKC-DIC; June 2020.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115.
- 6. USPDI, Micromedex; 2021.
- 7. Facts and Comparisons eAnswers (online); 2021 Clinical Drug Information, LLC.